Howard Mayer, M.D., is Senior Vice President and Head of Global Clinical Development at Shire in Lexington, MA. Howard joined Shire in May 2012, from EMD (Merck KGaA) Serono where since 2009 he was Chief Medical Officer. Before joining EMD Serono, Howard was at Pfizer for nearly eight years, where he held a variety of global roles including Head of Clinical Development and Medical Affairs, for Virology/Infectious Diseases. While at Pfizer, Howard led the clinical development program of Selzentry, a novel CCR5 antagonist for the treatment of HIV, and in 2011 he was recognized by PharmaVoice as being one of the 100 Most Inspiring People in the Life Sciences Industry. Prior to joining Pfizer, Howard was at Bristol-Myers Squibb for five years, where he was Director of Infectious Diseases Clinical Research. Howard obtained his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital in New York and an Infectious Diseases fellowship at Harvard Medical School. Howard is on the Scientific Advisory Boards of Macrolide Pharmaceuticals, and Arsanis Biosciences, and has served on the Board of Autism Speaks in New England since 2011.